Cell-free protein production can be done using various kinds and species of cell lysates. Such methods offer various benefits and features over conventional in vivo methods such as rapid and high-throughput expression process, no requirement of gene transfection step and cell culture or extensive protein purification, isotopic labeling of proteins, and production of functional virions or toxic polypeptides.
The global cell-free protein expression market is estimated to account for US$ 318.9 Mn in terms of value by the end of 2027.
Global Cell-free Protein Expression Market: Drivers
Increasing demand for cell-free protein expression in proteomics and biologics is expected to boost growth of the global cell-free protein expression market over the forecast period. The simple presentation of cell-free protein expression system facilitates its easier integration into high throughput platforms for efficient biologics and proteomics studies. Moreover, cell-free protein expression systems, being an open system, allows addition of various natural and unnatural components to the reaction mixture, such as reducing/oxidizing elements, chaperones, labeled amino acids, or detergents making it an appropriate choice for different proteomics studies.
Global Cell-free Protein Expression Market: Restraints
Lack of eukaryotic co- and post-translational modifications is expected to hamper hinder growth of the global cell-free protein expression market. Prokaryotic cell-free systems such as E. coli and wheat germ extracts are incapable of carry out humanized glycosylation patterns. Mammalian membrane protein such as canine microsomal membranes must be added to the translation mix in order to produce glycosylated proteins with rabbit reticulocyte systems. However, this can lead to low protein yield and increased cost.
Use of cell-free protein expression system in R&D of neurological disorders is expected to offer lucrative growth opportunities for players in the global cell-free protein expression market. For instance, in January 2018, researchers from European Molecular Biology Laboratory, The University of New South Wales, and The University of Queensland, reported use of cell-free protein expression system in evaluating the effect of β-synuclein – a protein that is encoded by the SNCB gene – on the aggregation of five α-Synuclein pathological mutants linked to early-onset Parkinson’s disease.
The E.coli Cell-free Protein Expression System segment in the global cell-free protein expression market was valued at US$ 88.6 Mn in 2019 and is expected to reach US$ 140.1 Mn by 2027 at a CAGR of 5.9% during the forecast period. Increasing demand for cell-free protein expression in proteomics and biologics is expected to boost growth of the segment during the forecasted period.
The Protein Purification segment held dominant position in the global cell-free protein expression market in 2019, accounting for 38.9% share in terms of value, followed by Protein Labelling, respectively. Increasing prevalence of infectious diseases and cancer is expected boost the growth of the segment during the forecast period.
The use of cell-free expression has increased in production of biologics as the approach reduces process development requirements and requires minimal manufacturing infrastructure. Moreover, cell-free expression can be used to express multiple products within a short timeframe.
Cell-free protein expression systems have advanced considerably over the last decades and progresses in protein yield have resulted in their usage for in-vitro protein production in laboratories. The continuous expression mode for protein synthesis, especially in wheat germ lysates, is being highly accepted for production in industrial scale. These methods can widely help in producing proteins of high commercial value such as hormones, diagnostic enzymes, and vaccines with high level of purity and lesser process steps.
Global Cell-free Protein Expression Market: Competitive Landscape
Major players operating in the global include, Thermo Fisher Scientific, Inc., Takara Bio, Inc., Promega Corporation, New England Biolabs, Jena Bioscience GmbH, GeneCopoeia, Inc., Cube Biotech GmbH, CellFree Sciences Co., Ltd., Moderna Therapeutics, Biotechrabbit GmbH, and Bioneer Corporation.
Global Cell-free Protein Expression Market: Key Developments
January 2020: Takara Bio Inc. announced completion of a new facility, the Center for Gene and Cell Processing II for the research and manufacturing of regenerative medicine products in Japan
July 2018: Moderna Therapeutics, a clinical-stage biotechnology, announced the opening of its state-of-the-art manufacturing facility in Norwood, Massachusetts (U.S.)
Scope of the report
Joining thousands of companies around the world committed to making the Excellent Business Solutions.